4D Molecular Therapeutics, Inc. (FDMT)
|Net Income (ttm)||-56.69M|
|Trading Day||April 22|
|Day's Range||33.10 - 36.28|
|52-Week Range||30.55 - 55.11|
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Hig...
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fa...
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to P...
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based compan...
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
4D Molecular Therapeutics is a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved vectors are invented with the goal of being delivered through clinically routine, we... [Read more...]
|IPO Date |
Dec 11, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, FDMT's revenue was $13.61 million, an increase of 94.85% compared to the previous year's $6.99 million. Losses were -$56.69 million, 15.0% more than in 2019.
The average 12-month stock price forecast for FDMT is 56.00, which is an increase of 60.60% from the latest price.